Elite Pharmaceuticals announced the US Food and Drug Administration’s acceptance for review of an Abbreviated New Drug Application on December 21, 2023, for an undisclosed generic drug product in a class of medications known as central nervous stimulants.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELTP: